## In the Claims:

## Claims

- 1. (Currently Amended) <u>A isopropanol</u> <u>Isopropanol</u>/water mixed solvate of olanzapine which contains 2 molecules of water and 1 molecule-of isopropanol per 2 molecules of olanzapine.
- 2. (Currently Amended) <u>The isopropanol</u>/water mixed solvate of olanzapine <u>of claim</u> <u>1</u> characterized by the x-ray structure shown in Figure 1.
- 3. (Currently Amended) <u>The isopropanol Isopropanol</u> /water mixed solvate of olanzapine <u>of claim</u> <u>1</u> characterized by a NMR spectrum in CDC1<sub>3</sub> showing peaks at approximately 1.20 ppm, 2.20-2. 40 ppm and 4.03 ppm.
- 4. (Currently Amended) <u>The isopropanol Isopropanol</u> /water mixed-solvate of olanzapine <u>of claim 1</u> characterized by the NMR spectrum shown in Figure 2.
- 5. (Currently Amended) Process A process for the preparation of the isopropanol/water mixed solvate of olanzapine according to any one of claims 1 to 4claim 1, which comprises crystallizing it from a solvent mixture comprising isopropanol and water in a ratio of at least 9 to 1 parts by volume.
- 6. (Currently Amended) <u>Process The process according to claim 5</u>, wherein the solvent mixture comprises isopropanol and water in a ratio of at least 20 to 1 parts by volume.

- 7. (Currently Amended) <u>Process The process</u> according to claim 5 or 6, wherein the solvent mixture comprises isopropanol and water in a ratio of at least 35 to 1 parts by volume.
- 8. (Currently Amended) Process according to any one of claims 5 to 7claim 5, wherein the crystallization is effected by adding the water to a solution comprising olanzapine and the isopropanol.
- 9. (Currently Amended) <u>Process</u> for the preparation of form I olanzapine, wherein the isopropanol/water mixed solvate according to <u>any one of claims 1 to 4 claim 1</u> is used.
- 10. (Currently Amended) <u>Process The process according to claim 9</u>, wherein (a) the isopropanol/water mixed solvate is converted to a methylene chloride solvate of olanzapine, and (b) the methylene chloride solvate is converted to form I olanzapine.
- 11. (Currently Amended) <u>Process The process according to claim 10</u>, wherein in step (a) a solution of the isopropanol/water mixed solvate in methylene chloride is prepared, the solvent is partly evaporated and the remaining solution is cooled.
- 12. (Currently Amended) Process The process according to claim 10, wherein in step (a) a solution of the isopropanol/water mixed solvate in methylene chloride is prepared, a drying agent is added to the solution, the drying agent is removed from the mixture and the methylene chloride solvate of olanzapine is recovered.

- 13. (Currently Amended) <u>Process</u> <u>The process</u> according to claim 12, wherein anhydrous CaSO<sub>4</sub> is used as <u>the</u> drying agent.
- 14. (Currently Amended) Process The process according to any one of claims 10 to 13 claim 10, wherein the methylene chloride solvate is methylene chloride hemisolvate of olanzapine.
- 15. (Currently Amended) Process The process according to any one of claims 10 to 14claim 10, wherein in step (b) the methylene chloride solvate is suspended in isopropanol.
- 16. (Currently Amended) <u>Process The process according to claim 15</u>, wherein the ratio between methylene chloride solvate (kg) and isopropanol (1) is 1: 5 to 1: 2.
- 17. (Currently Amended) Process The process according to any one of claims 10 to 16 claim 14, wherein in step (b) methylene chloride hemisolvate is dried under vacuum at a temperature of 30 to 55 C for 6 to 36 hours, the dried hemisolvate is suspended in isopropanol, the suspension is stirred at a temperature of 15 to 35 C for 15 to 60 min, and the form I olanzapine is separated.
- 18. (Currently Amended) <u>Process</u> <u>The process</u> according to claim 9, wherein the solid isopropanol/water mixed solvate of olanzapine is mixed with solid olanzapine of form I and the particle size of the mixture is reduced.
- 19. (Currently Amended) <u>Process The process according to claim 18</u>, wherein the mixture comprises up to 10% and in particular up to 5% by weight of form I olanzapine.

- 20. (Currently Amended) Process The process according to claim 18 or 19, wherein the mixture of reduced particle size is dried in a vacuum drier at temperatures ranging from room temperature to 80 C, preferably from room temperature to 60 C and most preferred from 40 to 50 C.
- 21. (Currently Amended) <u>Process The process according to claim 20</u>, wherein the dried material is suspended in isopropanol, the solid is separated by filtration and dried.
- 22. (Currently Amended) <u>Process The process according to claim 21</u>, wherein the dried material is suspended in isopropanol in a weight (kg) to volume (1) ratio of 1: 5 to 1: 2, in particular 1: 3 to

1:2.

- 23. (Currently Amended) Process The process for the preparation of any other solvate or hydrate forms of olanzapine, or mixtures thereof, wherein the isopropanol/water mixed solvate of olanzapine according to any one of claims 1 to 4 claim 1 is used.
- 24. (Currently Amended) Process The process for the preparation of anhydrous forms of olanzapine, wherein the isopropanol/water mixed solvate of olanzapine according to any one of claims 1 to 4 claim 1 is used.
- 25. (Currently Amended) Use-The use of the isopropanol/water mixed solvate of olanzapine according to any one of claims 1 to 4 claim 1 for the preparation of any other solvate or hydrate

forms of olanzapine, or mixtures thereof, or for the preparation of anhydrous forms of olanzapine.

- 26. (Currently Amended) Process A process for preparing form I olanzapine, wherein at least one of (a) a precursor for olanzapine form I and (b) olanzapine form I is crystallized or precipitated from a liquid medium which medium is present in a container wherein the surfaces of the container contacting the medium are comprising at least one polymer
- 27. (Currently Amended) <u>Process The process according to claim 26</u>, wherein a precursor for olanzapine from I is crystallized or precipitated.
- 28. (Currently Amended) <u>Process The process according to claim 27</u>, wherein the precursor is methylene chloride hemisolvate of olanzapine.
- 29. (Currently Amended) Process The process according to any one of claims 26 to 28claim 26, wherein the precursor or the olanzapine form I has been prepared using the isopropanol/water mixed solvate according to any one of claims 1 to 4claim 1.
- 30. (Currently Amended) Process according to any one of claims 26 to 29 claim 26, wherein the surfaces of the container contacting the medium are consisting of at least one polymer.
- 31. (Currently Amended) <u>Process The process according to any one of claims 26 to 30 claim 26</u>, wherein the polymer contains fluorine.

32. (Currently Amended) <u>Process The process according to any one of claims 26 to 31 claim 26</u>, wherein the polymer is selected from polytetrafluoroethylene, fluorinated ethylen<u>e</u> propylene copolymer, perfluor alkoxy polymer, or ethylene tetrafluoroethylene copolymer.